OCX stock news

Does the July share price for OncoCyte Corporation (NYSEMKT:OCX) reflect what it's really worth? Today, we will… Read more
OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes. Read more
OCX earnings call for the period ending March 31, 2019. Read more
OncoCyte Corporation (NYSEMKT:OCX) Q1 2019 Earnings Conference Call May 14, 2019, 04:30 PM ET Company Participants Bob Yedid - IR, LifeSci Advisors William Anne Read more

OncoCyte beats by $0.01

08:24pm, Tuesday, 14'th May 2019
Read more
ALAMEDA, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE: OCX ) , a developer of novel, non-invasive tests for the early detection of cancer, today announced the successful completion of the Company's Analytical Validation study and the commencement of a CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer. The Analytical Validation Study was designed to establish performance characteristics of the ThermoFisher Next-Generation Sequencing assay system in OncoCyte's Clinical Laboratory. The studies required for Analytical Validation have been established in the CLSI (Clinical Laboratory Standards Institute) Guidelines. These guidelines cover the testing for such matters as limits of quantitation, precision, reproducibility, and interfering substances. OncoCyte has completed all of these studies successfully. The Analytical Validation data supports the robust performance of DetermaVu™, previously demonstrated in the R&D Validation study earlier this year. Read more
Looking at the indicators on shares of Oncocyte Corp (OCX), we see that the PPO is above the signal line. Technical traders might be on the lookout for the stock to display signs of a bullish breakout Read more
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) and OncoCyte Corporation (NYSEAMERICAN:OCX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst reco Read more
Both OncoCyte Corporation (NYSEAMERICAN:OCX) and Spark Therapeutics Inc. (NASDAQ:ONCE) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards t Read more
Pluristem Therapeutics Inc. (NASDAQ:PSTI) and OncoCyte Corporation (NYSEAMERICAN:OCX) are two firms in the Biotechnology that compete against each other. Below Read more

OncoCyte misses by $0.02

08:08pm, Monday, 01'st Apr 2019
OncoCyte (OCX): Q4 GAAP EPS of -$0.11 misses by $0.02. Cash & equivalents of $8.03M (+5.7% Y/Y) Press Release Read more

OncoCyte misses by $0.02

08:08pm, Monday, 01'st Apr 2019
OncoCyte (OCX): Q4 GAAP EPS of -$0.11 misses by $0.02. Cash & equivalents of $8.03M (+5.7% Y/Y) Press Release Read more

Proudly made at

ROCKIT